Llc ?sentiss Rus?

Llc "Sentiss Rus" is a pharmaceutical importer and buyer based in Moscow, Russia. It operates as a subsidiary of Sentiss Pharma Private Limited, an Indian pharmaceutical company established in 1994. Sentiss Pharma specializes in manufacturing and distributing a range of pharmaceutical products, including ophthalmic, respiratory, otolaryngological, and wound care solutions.

As an importer, Llc "Sentiss Rus" plays a pivotal role in facilitating the distribution of Sentiss Pharma's finished pharmaceutical formulations within the Russian market. This includes a diverse portfolio of products such as tablets, capsules, syrups, and injections, catering to various therapeutic categories. The company's operations are integral to ensuring the availability of these products to meet the healthcare needs of the Russian population.

Llc "Sentiss Rus" maintains a strategic distribution network to effectively supply pharmaceutical products across Russia. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's operations are centralized in Moscow, facilitating efficient distribution throughout the country. The proximity to major transportation hubs in Moscow enables streamlined logistics, ensuring timely delivery of products to various regions within Russia.

The distribution network is designed to support the extensive range of products imported from India, ensuring that finished pharmaceutical formulations reach healthcare providers and consumers promptly. This infrastructure is crucial for maintaining the supply chain's integrity and meeting the demand for quality pharmaceutical products in the Russian market.

Llc "Sentiss Rus" functions primarily as a pharmaceutical importer and distributor within Russia's healthcare sector. By sourcing finished pharmaceutical formulations from its parent company, Sentiss Pharma Private Limited, the subsidiary ensures the availability of a wide array of pharmaceutical products in the Russian market. This role is essential in bridging the gap between the manufacturing capabilities of Sentiss Pharma and the distribution requirements of the Russian healthcare system.

The company's position in the supply chain underscores its importance in maintaining the flow of pharmaceutical products from production to end-users. Through its import and distribution activities, Llc "Sentiss Rus" contributes significantly to the accessibility of quality healthcare solutions across Russia.

Llc "Sentiss Rus" exhibits a high degree of sourcing concentration, importing 97.8% of its products from a single supplier, Sentiss Pharma Private Limited. This exclusive sourcing strategy indicates a deep-rooted partnership and reliance on Sentiss Pharma for the supply of finished pharmaceutical formulations.

While such concentration can lead to favorable terms and streamlined operations, it also presents potential risks. Any disruptions in Sentiss Pharma's production or supply chain could directly impact Llc "Sentiss Rus"'s ability to meet market demand. However, the consistent volume of shipments and the long-standing relationship between the two entities suggest a stable and reliable supply chain.

The shipment data reveals a robust and dependable relationship, with 254 shipments over the period from 2022 to 2026. This consistency reflects effective coordination and mutual trust, mitigating potential risks associated with single-source dependency.

The resilience of Llc "Sentiss Rus"'s supply chain is closely tied to its exclusive sourcing from Sentiss Pharma Private Limited. This singular supplier relationship necessitates a high level of trust and reliability. While the lack of backup suppliers could pose challenges in the event of supply disruptions, the established partnership and consistent shipment history indicate a well-functioning and dependable supply chain.

The diversity of formulations imported, encompassing 514 unique products, demonstrates a comprehensive approach to meeting the varied pharmaceutical needs of the Russian market. This breadth of product offerings enhances the supply chain's resilience by catering to a wide range of therapeutic areas.

The shipping routes primarily involve direct connections between India and Russia, leveraging established logistics channels to ensure timely deliveries. Both countries' adherence to international trade agreements and regulatory standards further bolsters the supply chain's stability and compliance.

The sourcing pattern of Llc "Sentiss Rus" reflects a strategic decision to maintain a focused and efficient supply chain by partnering exclusively with Sentiss Pharma Private Limited. This approach likely results in favorable terms, streamlined operations, and a unified product portfolio, enhancing the company's competitive position in the Russian pharmaceutical market.

For Indian exporters aiming to become alternative suppliers to Llc "Sentiss Rus," understanding the existing partnership dynamics is crucial. While the current exclusivity presents challenges, offering complementary products or specialized formulations not currently supplied by Sentiss Pharma could create opportunities. Building a strong value proposition and demonstrating reliability and quality would be essential steps in establishing a foothold in this market segment.

In Russia, the primary regulatory authority overseeing pharmaceutical imports is the Ministry of Health of the Russian Federation. This body is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the Russian market.

Key legislation governing pharmaceutical imports includes the Federal Law on Circulation of Medicines, which outlines the requirements for the registration, importation, and distribution of medicinal products. Additionally, the Technical Regulations of the Customs Union (TR CU 021/2011) set forth safety requirements for medical devices and pharmaceutical products.

The marketing authorization pathway for Indian generics involves obtaining a Certificate of State Registration from the Ministry of Health. This process includes submitting comprehensive documentation, such as clinical trial data, manufacturing details, and quality control measures, to demonstrate compliance with Russian standards.

Import licensing requirements for pharmaceutical products in Russia mandate that all imported medicines be registered with the Ministry of Health. This registration process ensures that imported products meet the necessary safety and efficacy standards.

Good Manufacturing Practice (GMP) certification is a critical component of the import process. Russia recognizes GMP certificates from the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications attest to the manufacturing facility's adherence to international quality standards.

Wholesale distribution authorization is also required for entities involved in the distribution of pharmaceutical products within Russia. This authorization ensures that distributors comply with regulatory requirements and maintain the integrity of the pharmaceutical supply chain.

Imported pharmaceutical products must undergo batch testing to verify their quality and compliance with Russian standards. This testing ensures that each batch meets the required specifications for safety, efficacy, and quality.

Stability requirements are also enforced to ensure that pharmaceutical products maintain their intended quality throughout their shelf life. This includes testing under various conditions to confirm the product's stability and effectiveness.

Labeling language requirements stipulate that all product labels be in Russian, providing essential information to consumers and healthcare professionals. Serialization mandates are implemented to enhance traceability and prevent counterfeit products from entering the market. These measures are part of Russia's efforts to maintain the integrity and safety of its pharmaceutical supply chain.

Between 2024 and 2026, Russia has implemented several policy changes affecting pharmaceutical imports. These include updates to the Federal Law on Circulation of Medicines, introducing stricter requirements for the registration and importation of pharmaceutical products. Additionally, the Ministry of Health has enhanced its oversight of GMP certifications, requiring more detailed documentation and periodic audits of manufacturing facilities.

These regulatory changes aim to strengthen the quality control of imported pharmaceuticals and ensure that only products meeting the highest standards are available in the Russian market. For Indian exporters, staying informed about these developments is crucial to ensure compliance and maintain uninterrupted access to the Russian market.

Llc "Sentiss Rus" focuses on importing a range of pharmaceutical products, with a significant emphasis on antibiotics, advanced antibiotics, and corticosteroids. This strategic focus aligns with the therapeutic needs prevalent in the Russian healthcare system, addressing common and critical health conditions.

The market demand for these therapeutic areas is driven by factors such as the prevalence of infectious diseases, respiratory conditions, and inflammatory disorders in Russia. By concentrating on these categories, Llc "Sentiss Rus" ensures that it meets the essential healthcare needs of the population, contributing to improved health outcomes.

Llc "Sentiss Rus" employs a sourcing strategy centered on generic drug formulations, primarily sourced from its parent company, Sentiss Pharma Private Limited. This approach allows the company to offer cost-effective pharmaceutical products without compromising on quality.

The preference for specific formulations, such as antibiotics and corticosteroids, reflects the company's commitment to addressing prevalent health issues in the Russian market. India's established reputation for producing high-quality generic pharmaceuticals positions it as a strategic partner in Llc "Sentiss Rus"'s procurement strategy.

Based on its product mix, Llc "Sentiss Rus" serves a broad segment of the Russian pharmaceutical market, including retail pharmacies, hospitals, and wholesale distribution channels. The company's diverse product portfolio